Shiver John W. 4
4 · NOVAVAX INC · Filed Mar 12, 2026
Research Summary
AI-generated summary of this filing
Novavax (NVAX) Director John Shiver Exercises RSUs (7,947 shares)
What Happened
- John W. Shiver, a director of Novavax, had 7,947 derivative units convert into 7,947 shares on March 10, 2026 (transaction code M). The filing reports an acquisition of 7,947 shares at $0.00 and a simultaneous disposition of 7,947 shares at $0.00. Total cash consideration reported is $0, indicating these were award conversions rather than an open-market purchase or a cash sale.
Key Details
- Transaction date: 2026-03-10; Form 4 filed 2026-03-12 (timely).
- Acquired: 7,947 shares via conversion/exercise (price $0.00). Disposed: 7,947 shares (price $0.00).
- Total reported value: $0 (per the Form 4 entries).
- Shares owned after the transaction: not specified in the provided excerpt.
- Footnote: The RSUs subject to this grant vest one-third on each of the first three anniversaries of March 10, 2025, subject to continued board service.
- Filing timeliness: filed within the standard Form 4 window (no late-filing flag reported).
Context
- The M code and $0 price here are consistent with conversion/vesting of equity awards (RSUs) rather than a market purchase. Filings that show identical acquired and disposed share counts at $0 often reflect shares issued on vesting with an equivalent number withheld or surrendered to cover taxes or other obligations. This is a routine director equity-vesting event and not a cash investment or open-market sale.
Insider Transaction Report
Form 4
NOVAVAX INCNVAX
Shiver John W.
Director
Transactions
- Exercise/Conversion
Common Stock
2026-03-10+7,947→ 7,947 total - Exercise/Conversion
Restricted Stock Units
[F1]2026-03-10−7,947→ 15,893 totalExercise: $0.00Exp: 2035-03-10→ Common Stock (7,947 underlying)
Footnotes (1)
- [F1]The RSUs subject to this grant under the Restated 2015 Stock Incentive Plan will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of March 10, 2025, in each case subject to continued service on the Company's Board of Directors through such vesting date
Signature
/s/ Mark J. Casey, Attorney-in-Fact|2026-03-12